Skip to main content
. Author manuscript; available in PMC: 2013 Jun 18.
Published in final edited form as: Proteomics Clin Appl. 2011 Sep 7;5(0):532–541. doi: 10.1002/prca.201000089

Table 3.

Longitudinal samples used for the independent validation of the HRNB classifier.

Pt
No.
Pt Info Time Point Disease
Status
Sites of
Disease
Prediction Correct?
1 M, 12 mo, MNA
Diagnosis Present ST, B, BM Disease Yes
On Therapy Present ST, B Disease Yes
Progression Present ST, B, BM Disease Yes
On Therapy Not Present Disease No
Relapse Present ST, B, BM Disease Yes

2 F, 12 mo, MNA
Diagnosis Present ST, B, BM Disease Yes
On Therapy Present ST, B, BM Disease Yes
On Therapy Not Present No Disease Yes
Off Therapy Not Present No Disease Yes

3 F, 52 mo, MA
Diagnosis Present ST, B Disease Yes
On Therapy Not Present No Disease Yes
On Therapy Not Present No Disease Yes

4 M, 24 mo, MA
Diagnosis Present ST1 Disease Yes
On Therapy Not Present No Disease Yes
On Therapy Not Present No Disease Yes
Off Therapy Not Present No Disease Yes

5 F, 22 mo, MA
Diagnosis Present ST1 Disease Yes
Relapse Present ST Disease Yes
Progression Present ST, B, BM Disease Yes

6 M, 14 mo, MA
Diagnosis Present ST, B2 No Disease No
On Therapy Not Present No Disease Yes
On Therapy Not Present No Disease Yes
Off Therapy Not Present Disease No

7 M, 55 mo, MA
Diagnosis Present ST, B, BM Disease Yes
On Therapy Present ST, B, BM Disease Yes
On Therapy Present ST, BM Disease Yes
On Therapy Present BM Disease Yes
On Therapy Present ST, BM No Disease No

Pt info: M=male, F=female; mo=age in months at diagnosis; MA=MYCN amplified; MNA=MYCN not amplified. Sites of Disease: ST=soft tissue; B=Bone; BM=Bone Marrow.

1

Stage 3

2

No Primary Tumor.